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Background: Exfoliative cheilitis is a condition of unknown etiology characterized by hyperkeratosis and scaling
of vermilion epithelium with cyclic desquamation. It remains largely refractory to treatment, including cortico-
steroid therapy, antibiotics, antifungals, and immunosuppressants.
Objective:We sought to evaluate the safety and efﬁcacy of excimer laser therapy and narrowband ultraviolet B
therapy in female patients with refractory exfoliative cheilitis.
Methods: We reviewed the medical records of two female patients who had been treated unsuccessfully for
exfoliative cheilitis.We implemented excimer laser therapy, followed by hand-held narrowbandUVB treatments
for maintenance therapy, and followed them for clinical improvement and adverse effects.
Results: Both patients experienced signiﬁcant clinical improvement with minimal adverse effects with excimer
laser therapy 600-700 mJ/cm2 twice weekly for several months. The most common adverse effects were
bleeding and burning,which occurred at higher doses. The hand-held narrowbandUVB unitwas also an effective
maintenance tool.
Limitations: Limitations include small sample size and lack of standardization of starting dose and dose increments.
Conclusion: Excimer laser therapy is a well-tolerated and effective treatment for refractory exfoliative cheilitis with
twiceweekly laser treatments of up to 700mJ/cm2. Transitioning to thehand-held narrowbandUVBdevicewas also
an effective maintenance strategy.
© 2015 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Exfoliative cheilitis is a chronic inﬂammatory disorder of unknown
etiology characterized by scaling, hyperkeratosis, and crusting due to
desquamation of the vermilion epithelium (Daley and Gupta, 1995;
Rogers and Bekic, 1997; Thomas et al., 1983). First in 1983 and again in
1998, exfoliative cheilitis was deﬁned as a cyclic desquamation of the
lips without evidence of factitial sources of irritation such as lip
licking or biting, infection, or allergens as the primary etiology of the
desquamation (Taniguchi and Kono, 1998; Thomas et al., 1983). Early
literature suggested a female predisposition for the condition, particu-
larlywhen exfoliative and factitious cheilitis were used interchangeably
and when exfoliative cheilitis was found to be associated with under-
lying psychiatric disorders (Crotty and Dicken, 1981; Daley and Gupta,
1995; Taniguchi and Kono, 1998; Thomas et al., 1983). A recent retro-
spective study found a 2:1 female–male ratio in exfoliative cheilitis
cases diagnosed from 2000 to 2010 (Almazrooa et al., 2013). In anyer Inc. on behalf of Women's Der
.population, the condition is generally refractory to treatment. We
sought to evaluate the safety and efﬁcacy of excimer laser therapy and
a hand-held ultraviolet B (UVB) device for exfoliative cheilitis.Methods
Two female patients with refractory exfoliative cheilitis were identi-
ﬁed. The ﬁrst patient is a 28-year-old female with a history of mild
atopic dermatitis as a child who presented with a 2-year history of
dry, cracking, and peeling lips. Her condition was so severe that she
was placed on disability due to pain and difﬁculty eating and speaking.
Bacterial and fungal cultures were negative. She had minimal response
to topical corticosteroids, topical antibiotics, and topical and oral anti-
fungals in the past (Table 1). Topical desoximetasone, oral mycopheno-
late mofetil, and topical calcipotriene 0.005% cream were tried in
succession, but all had to be discontinued due to irritation and/or poor
response. She tolerated a 9-day prednisone pulse tapered from 60 mg
daily and tretinoin 0.025% creamwith no adverse effects and moderate
improvement. Throughout these treatments, she also concurrently used
over-the-counter topical products (Table 1). Initial physical exam
revealed dry mouth and scaling on lips with minimal erythema.matologic Society. This is an open access article under the CC BY-NC-ND license
Table 1
Patient 1: Previous Treatments.
Treatment Category Medications Previously Used
Topical corticosteroids Betamethasone
Clobetasol
Desoximetasone
Topical antibiotics Metronidazole gel
Topical antifungals Name unknown
Topical retinoids Tretinoin
Topical vitamin D analogs Calcipotriene
Systemic antifungals Name unknown
Systemic steroids Dexamethasone
Prednisone
Immunomodulators Mycophenolate mofetil
Over-the-counter products Olive oil
Safﬂower oil
Vaseline
Fig. 1. A, Exfoliative cheilitis. Patient 1 before beginning excimer laser therapy, with thick
scaling and hyperkeratosis. B, Exfoliative cheilitis. Patient 1 showing signiﬁcant improve-
ment in scaling and dryness after completing 8 months of excimer therapy.
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speckled pattern and low titer (1:80) and an elevated rheumatoid fac-
tor. Histologic examination showed subacute spongiotic dermatitis
with eosinophils. Patch testing revealed 1-2+ reactions to fragrance
mix, cinnamic alcohol, amyl cinnamyl alcohol, and carvone, and trace
reaction to shellac and triethanolamine. Patient was placed on a low-
fragrance diet, and both she and her signiﬁcant other exclusively used
products that did not contain the allergens to which she was allergic.
Her condition did not respond to allergen avoidance.
The second patient is a 39-year-old female who presented with
cheilitis for 15 years with frequent peeling and minute vesiculation
limited to the transitional zone of the lip. Initially, the patient described
frequently licking and biting her lips, but after stopping this habit, the
peeling and ﬂaking persisted. She had a history of asthma as a child,
negative airborne allergy and food allergy testing, and a negative
North American series patch test. Her only oralmedicationwas omepra-
zole. In the past, she was treated in the United States, Europe, and Asia
by multiple dermatologists. She had used systemic and topical cortico-
steroids, systemic and topical antibiotics, topical antifungals, multiple
vitamin supplements, and various miscellaneous topicals without
signiﬁcant improvement (Table 2). Initial physical exam revealed scale
on bilateral lips with minimal inﬂammation and postinﬂammatory
hypopigmentation. Her lips had been biopsied several times, and the
most recent biopsy from 2007 revealed spongiotic dermatitis.Table 2
Patient 2: Previous Treatments.
Treatment Category Medications Previously Used
Topical corticosteroids Betamethasone
Clobetasol
Desonide
Dexamethasone
Flumethasone
Fluticasone
Hydrocortisone
Topical antibiotics Ciproﬂoxacin
Gentamicin
Topical antifungals Tinidazole
Systemic antibiotics/antiparasitics Cefprozil
Ciproﬂoxacin
Mebendazole
Tetracycline
Systemic steroids Prednisone
Miscellaneous topicals Fusidic acid
Salicylic acid
Vitamin supplements Calcium pantothenate
Folic acid
Nicotinamide
Vitamins B1, B2, B6, B12
Vitamin CAll topical medications were stopped, and patients began excimer
laser therapy twice weekly. The ﬁrst patient started at a dose of
400 mJ/cm2, increasing by 5 to 10% per treatment up to a maximum
of 944 mJ/cm2. The second patient started at 300 mJ/cm2, increasing
in 5 to 20% increments up to 724 mJ/cm2. Photographs of patients’ lips
were taken before initiating laser treatment and at various points
throughout treatment to monitor progress (Figs. 1A-B and 2A-B).
Results
Clinical improvement of scaling and discoloration was noted within
ﬁve weeks of beginning excimer laser therapy at 300 to 400 mJ/cm2.
The ﬁrst patient began excimer laser therapy twiceweekly in December
2011 at a dose of 400mJ/cm2, and started to see improvement after the
third treatment at 462 mJ/cm2. Dose was increased by 5 to 10% per
treatment,which she toleratedwell up to a dose of 600mJ/cm2, resulting
in signiﬁcant improvement. She experienced some burning and blis-
tering at levels from 642 mJ/cm2 up to a peak dose of 944 mJ/cm2,
and continued to have some blistering and bleeding when her dose
was reduced to 610 mJ/cm2. She was further decreased to a mainte-
nance dose of 510mJ/cm2 with continuing clinical improvement and
fewer side effects, reserving increases up to 530mJ/cm2 for speciﬁc sites
where the patient had thicker, intact skin during her desquamation
cycle. Patient continued to have excellent clinical results, completing
52 total treatments with a nearly complete clinical response. She was
provided a hand-held narrowband UVB unit to use at home starting
August 2012 for maintenance. She continues to use this periodically,
approximately every 3 to 4 months, for approximately 1-to-3-week
intervals when the condition recurs, but reports that crusts remain
thinner and are no longer painful since completing excimer laser
therapy. The condition no longer impacts her activities of daily
living. Lip peeling remained mild at 23-month follow-up from dis-
continuation of the excimer laser therapy.
The second patient began excimer laser therapy twice weekly in
October 2012, starting at 300 mJ/cm2 and increasing by 5 to 20%
increments to 600 to 700 mJ/cm2. She experienced mild swelling
Fig. 2. A, Exfoliative cheilitis. Patient 2 before beginning excimer therapy, demonstrating
initial scaling and hypopigmentation. B, Exfoliative cheilitis. Patient 2 after 3 months of
excimer laser therapy and 6 months of home narrowband UVB therapy, with minimal
scaling and signiﬁcant improvement of hypopigmentation.
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was noted after 10 treatments, at 690 mJ/cm2. She reported some
blistering, burning, and pruritus at 690 to 724 mJ/cm2. Peak dose was
724 mJ/cm2. She was simultaneously applying Vaseline and desonide
0.05% ointment to the affected areas twice daily to alleviate pruritus.
In January 2013, she was transitioned to a hand-held narrowband
UVB unit after experiencing a partial clinical response with 15 treat-
ments. She began at 200 mJ/cm2 and increased by 10 mJ/cm2 incre-
ments up to three times/week up to a maximum of 700 mJ/cm2. Her
cheilitis was 60% improved by April 2013. She reached a newmaximum
of 750 mJ/cm2, with a therapeutic range of 500 to 750 mJ/cm2. The
patient experienced an 80% improvement by June 2013, after com-
pleting 3 months of excimer laser therapy and 6 months of home
therapy. She felt overall the excimer laser therapy was the most
effective of all the treatments she had tried and had stayed in remis-
sion at 18-month follow-up from discontinuation of the narrowband
UVB therapy at home.
Both patients experienced signiﬁcant resolution of scaling, crusts,
skin thickness, and lip discomfort at doses of up to 600 mJ/cm2. At
higher doses ranging from 610 to 944 mJ/cm2, patients experienced
the adverse effects of blistering, burning, and bleeding. Doses up to
600 mJ/cm2 were better tolerated when patients had thicker, intact
skin during their desquamation cycle.Discussion
Exfoliative cheilitis is a diagnosis of exclusion. Patients will describe
a cyclic desquamation of the lips despite minimizing factitial sources of
irritation, such as lip licking or biting. It is important to rule out sources
of allergic or irritant dermatitis, bacterial or candidal infection, and
cheilitis glandularis through biopsy, culture, and patch testing (Crotty
and Dicken, 1981; Reade and Sim, 1986; Reichart et al., 1997; Taniguchiand Kono, 1998; Thomas et al., 1983). Despite positive patch testing,
avoidance does not result in remission in this population, and they clas-
sically fail trials of topical steroids and oral antifungal and antibiotic
therapy (Crotty and Dicken, 1981; Daley and Gupta, 1995; Taniguchi
and Kono, 1998).
Many different therapies have been attempted to treat exfoliative
cheilitis. Among these are topical and systemic corticosteroids, antifun-
gals, immunosuppressants, cryotherapy, and radiation therapy, as well
as vitamins, petrolatum gels, mineral oils, and moisturizers, all which
have not been curative (Crotty andDicken, 1981; Connolly and Kennedy,
2004; Daley andGupta, 1995; Leyland and Field, 2004;Mani and Shareef,
2007; Reade and Sim, 1986; Reichart et al., 1997; Taniguchi and Kono,
1998; Thomas et al., 1983). Individual case reports have supported the
use of antidepressants (Crotty and Dicken, 1981; Leyland and Field,
2004; Mani and Shareef, 2007; Taniguchi and Kono, 1998), tacrolimus
(Connolly and Kennedy, 2004), and Calendula ofﬁcinalis ointment 10%
(Roveroni-Favaretto et al., 2009).
Excimer laser is a form of light therapy that delivers a very speciﬁc,
308-nm wavelength of monochromic ultraviolet B in high-intensity,
short impulses. Itsmain advantage is its precision, as it directly penetrates
affected skin without affecting surrounding healthy skin, and it may also
require fewer treatments than narrowband UVB therapy (Mudigonda
et al., 2012). It ismost commonly used for chronic, recalcitrant conditions
such as psoriasis, vitiligo, dermatitis, and mycosis fungoides (Mudigonda
et al., 2012). Excimer laser therapy is increasingly used in psoriasis due to
its ability to target chronic exfoliative processes. Studies have suggested
that the mechanism of action of the laser is to cause T-cell depletion by
affecting key mediators of apoptosis and decreasing the rate of prolifera-
tion of keratinocytes (Bianchi et al., 2003). This, in turn, results in de-
creased inﬂammation and desquamation from a clinical standpoint.
In this sense, exfoliative cheilitis may respond to excimer laser by a
similar mechanism as in psoriasis, as it involves chronic desquamation
of the lips. Our two patients presented with severe scaling and hyper-
keratosis in a desquamative cycle that was resistant to standard anti-
infectious and anti-inﬂammatory therapy. The practitioner can consider
the excimer laser as a novel therapy for exfoliative cheilitis, which is
effective because it addresses the underlying cyclic processes of scaling
and desquamation. It can result in signiﬁcant clinical improvement by
decreasing the rate of turnover the skin, perhaps by the same basic
mechanisms of action affecting T-cells and apoptosis in psoriasis.
In our experience, exfoliative cheilitis that is refractory to treatment
may beneﬁt from excimer laser therapy. Therapy twice weekly can
deliver results within 5 weeks, with progressive improvement seen
after several months. Based on these two cases, initial doses of 300
to 400mJ/cm2 can be incrementally increased to a maximum of
700 mJ/cm2, based on patient response and adverse effects such as
blistering, burning, and bleeding. Dosage may have to be adjusted at
each visit based on how much skin is present at the time of the laser
treatment (i.e., what point the patient is in during their desquamative
cycle). Excimer laser therapy has the potential to produce clinically
signiﬁcant results in patients with recalcitrant exfoliative cheilitis.
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